Taconic Capital Advisors L.P. said Friday it now owns a 7.46
percent stake in biopharmaceutical company Cephalon Inc. (CEPH),
which is the target of a $5.7 billion takeover bid by Canadian
drugmaker Valeant Pharmaceuticals International Inc. (VRX, VRX.TO).
view original article